Perspective Therapeutics (CATX) Cash from Operations (2010 - 2026)

Perspective Therapeutics has disclosed Cash from Operations across 17 years of filings, most recently posting -$20.6 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 3.49% year-over-year to -$20.6 million; the TTM figure through Jun 2026 stood at -$93.1 million (down 43.68% YoY), while the FY2025 annual figure was -$82.5 million, down 350.88% from the prior year.
• Cash from Operations came in at -$20.6 million for Q2 2026 at Perspective Therapeutics, up from -$31.5 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $13.8 million in Q1 2024 to a low of -$31.5 million in Q1 2026.
• Average Cash from Operations over 5 years is -$11.5 million, with a median of -$9.4 million recorded in 2023.
• Year-over-year, Cash from Operations surged 242.43% in 2024 and slumped 584.02% in 2025.
• Over 5 years, Cash from Operations stood at -$6.1 million in 2022, then sank by 48.01% to -$9.0 million in 2023, then plunged by 195.36% to -$26.6 million in 2024, then climbed by 7.33% to -$24.7 million in 2025, then grew by 16.25% to -$20.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$20.6 million in Q2 2026, -$31.5 million in Q1 2026, and -$24.7 million in Q4 2025.